Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Additional Reading from MarketBeat Media Wall Street Loves FIGS—Why Do Price Targets Predict Pullback?Submitted by Jennifer Ryan Woods. First Published: 3/4/2026. 
Key Points - FIGS stock has surged nearly 260% over the past year, hitting a price not seen since shortly after its 2021 IPO.
- Q4 revenue topped $200 million—the company's best quarter ever—with scrubwear sales up 35% and international sales jumping 55%.
- Despite the rally and bullish analyst commentary, the consensus price target sits almost 30% below current levels.
- Special Report: [Sponsorship-Ad-6-Format3]
After a stunning plunge following its 2021 IPO, medical and lifestyle apparel company FIGS, Inc. (NYSE: FIGS) has roared back to life, trading at a price it hasn't touched in nearly four years. The stock, now above $17, has surged almost 260% over the past year and climbed 58% in the last month alone. The rally has been driven by strong earnings and a wave of bullish analyst commentary. Yet despite that momentum, the consensus 12‑month price target sits at just $12.25—almost 30% below the current price. That raises the question: how much of FIGS' recovery is based on fundamentals and how much on momentum? A look at the company's history and recent results offers clues. The Wall Street Journal is asking whether a stock market crash is coming. Research from Weiss Ratings suggests the first half of 2026 could be very tough for certain stocks as a radical shift hits the market. Some of America's most popular names could take serious damage. Analysts have identified five stocks you should consider avoiding before this event plays out. If these are in your portfolio, you'll want to review your positions carefully. See the five stocks to avoid and learn what's driving this shift. Early investors got an initial windfall after the May 2021 IPO, which priced at $22 per share and rose to about $50 within a month. Demand for medical apparel spiked during the COVID‑19 pandemic, but as the crisis eased the shares reversed sharply and were trading below $8 within a year. In the following years the stock mostly traded in the single digits. After dipping below $4 in April 2025, FIGS began another upward move—this time sustained. Earnings Momentum Sparks Rally Steady gains after positive Q1 and Q2 2025 results set the stage, but the Q3 2025 report on Nov. 6 accelerated the rally. The company posted stronger‑than‑expected revenue growth, solid demand across its core business and healthy margins despite tariff pressures. FIGS also raised its full‑year guidance for net revenue and adjusted EBITDA margins. Wall Street rewarded the outlook: the stock climbed more than 30% the following week and Zacks Research upgraded the shares to Strong Buy from Hold. Momentum continued with the Q4 2025 earnings report issued on Feb. 26. The company reported a 33% jump in quarterly revenue—its best quarter ever—with sales topping $200 million. In the earnings call, management cited broad strength, including a growing active customer base and higher average order values. The company also noted a PR boost from outfitting Team USA's medical team at the Winter Olympics. Scrubwear, FIGS' core segment, was a standout: sales in that category, which make up more than three‑quarters of net revenue, rose 35%. International sales surged 55% and helped lift the quarter. For the year, net revenue rose 14% to a record $630 million. Although tariffs pressured gross margins, profitability remained strong—full‑year adjusted EBITDA margin beat the company's target by more than 200 basis points. Analysts Applaud Earnings and Outlook FIGS provided an upbeat outlook for the coming year, citing continued demand supported by growth in healthcare jobs, plans to expand into new international markets, prioritized growth initiatives across its businesses and an ongoing share buyback program. For fiscal 2026, the company expects net revenue to grow 10%–12% and to deliver improved profitability metrics. Analysts responded with a string of positive updates. Barclays raised its rating to Strong Buy from Hold, KeyCorp shifted to Overweight from Sector Weight with a $17 target, Goldman Sachs moved to Hold from Strong Sell, BTIG reiterated a Buy rating with a $15 target, and Telsey Advisory lifted its target to $15 from $9. FIGS Stock Pushes Past Price Targets Strong results and an upbeat outlook propelled FIGS to four‑year highs. The stock began climbing even before the Q4 release, jumping nearly 14% in the session ahead of the report. After the results, the rally intensified: the stock surged 24% on the first trading day following the report and added another 10% the next day. As of March 4, the stock was trading above $17—more than double Morgan Stanley's $8 target from January and slightly above KeyCorp's $17 target. The gap between bullish sentiment and relatively modest price targets suggests analysts like FIGS' improving fundamentals but remain cautious about valuation. At current levels, shares trade at a price‑to‑earnings ratio near 90, indicating much of the company's expected growth may already be priced in. There are few publicly traded direct peers to FIGS, but for context, lululemon athletica inc. (NASDAQ: LULU)—a dominant player in lifestyle apparel—trades at a P/E of under 12 (per MarketBeat comparisons). The bottom line: investors have rewarded FIGS' turnaround, but skepticism remains about whether the stock can sustain this run or if a pullback is likely.
| 
